礼来

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT) and Jade Biosciences (JBIO)
  TipRanks · 2026/10/1
• 公司公告
  MMAG: Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - MR CHEAH MIN LLY
  Bursa Malaysia · 2026/1/9
• 评级变动
  J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,371
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,330
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Form 144 | Eli Lilly and Co(LLY.US) Insider Proposes to Sell 347.25 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,440
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
  TipRanks · 2026/10/1
• 评级变动
  Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,440
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,430
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 公司公告
  MMAG: Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - MR CHEAH MIN LLY (Amended Announcement)
  Bursa Malaysia · 2026/1/12
• 评级变动
  RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,430
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,341
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,550
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,600
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。